Home > Maligne hematologie > Lymfoïde ziekten > Plasmaceldyscrasieën > Multipel myeloom > Cartitude 4 / 68284528MMY3002

Printen

Versie:	1.0.0
Revisie:	30-09-2022
Type:	Studie
Status:	Gesloten voor inclusie
Ziektebeeld:	Multipel myeloom
Behandellijn:	>= 2de lijn
Fase:	Fase 3
Leeftijd:	≥ 18
PI:	Dr. W.W.H. Roeloffzen
TC:	M. de Vries
Titel:	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Cartitude 4 / 68284528MMY3002

Studieprotocol

Protocol Cartitude 4 / 68284528MMY3002

ICF

ICF Cartitude 4 / 68284528MMY3002

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Cartitude 4 / 68284528MMY3002

Hematologie Groningen